Five Prime Therapeutics, Inc. (FPRX): Price and Financial Metrics


Five Prime Therapeutics, Inc. (FPRX)

Today's Latest Price: $6.12 USD

0.29 (-4.52%)

Updated Jul 2 4:00pm

Add FPRX to Watchlist
Sign Up

Overall POWR Rating


POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank


Industry Rank:

Ranked of 336 in Biotech

See all "A" rated Strong Buy stocks

FPRX Stock Summary

  • The capital turnover (annual revenue relative to shareholder's equity) for FPRX is 0.13 -- better than only 13.98% of US stocks.
  • FPRX's price/sales ratio is 12.46; that's higher than the P/S ratio of 89.49% of US stocks.
  • Revenue growth over the past 12 months for Five Prime Therapeutics Inc comes in at -21.07%, a number that bests only 9.77% of the US stocks we're tracking.
  • Stocks that are quantitatively similar to FPRX, based on their financial statements, market capitalization, and price volatility, are APTX, RGNX, ASMB, RARE, and MEIP.
  • FPRX's SEC filings can be seen here. And to visit Five Prime Therapeutics Inc's official web site, go to www.fiveprime.com.
FPRX Daily Price Range
FPRX 52-Week Price Range

FPRX Stock Price Chart Technical Analysis Charts


FPRX Price/Volume Stats

Current price $6.12 52-week high $7.25
Prev. close $6.41 52-week low $1.75
Day low $6.08 Volume 243,440
Day high $6.58 Avg. volume 443,943
50-day MA $4.67 Dividend yield N/A
200-day MA $4.16 Market Cap 224.21M

Five Prime Therapeutics, Inc. (FPRX) Company Bio


Five Prime Therapeutics discovers and develops innovative therapeutics to improve the lives of patients with serious diseases. The company was founded in 2001 and is based in South San Francisco, California.


FPRX Latest News Stream


Event/TimeNews Detail
Loading, please wait...

FPRX Latest Social Stream


Loading social stream, please wait...

View Full FPRX Social Stream

Latest FPRX News From Around the Web

Below are the latest news stories about Five Prime Therapeutics Inc that investors may wish to consider to help them evaluate FPRX as an investment opportunity.

Is Five Prime Therapeutics Inc (FPRX) Going to Burn These Hedge Funds?

The latest 13F reporting period has come and gone, and Insider Monkey is again at the forefront when it comes to making use of this gold mine of data. Insider Monkey finished processing 821 13F filings submitted by hedge funds and prominent investors. These filings show these funds' portfolio positions as of March 31st, 2020. […]

Yahoo | June 26, 2020

The Daily Biotech Pulse: Sanofi Expedites COVID-19 Vaccine Timeline, Apyx Cleared For Market Expansion, Miragen's Positive Readout

The following is a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 22) ADC Therapeutics SA (NYSE: ADCT ) Adverum Biotechnologies Inc (NASDAQ: ADVM ) Aeglea Bio Therapeutics Inc (NASDAQ: AGLE ) Affimed NV (NASDAQ: AFMD ) - announced presentation at the AACR Virtual Meeting II, data on the Bristol-Myers Squibb Co (NYSE: BMY ) unit Genentech's RO7297089 and AFM24 developed from Affimed's ROCK platform Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY ) Amicus Therapeutics, Inc. (NASDAQ: FOLD ) Ascendis Pharma A/S (NASDAQ: ASND ) (presented at the AACR Virtual Meeting II with pre-clinical data for oncology product candidate) Atossa Therapeutics Inc (NASDAQ: ATOS ) Burning Rock Biotech Ltd (NASDAQ: BNR ) (announc...

Benzinga | June 23, 2020

Why Five Prime's Stock Is Trading Higher Today

Five Prime Therapeutics (NASDAQ: FPRX ) shares are trading higher on Monday after Wedbush upgraded the company's stock from Neutral to Outperform and raised its price target from $5 to $9. Five Prime Therapeutics is a biotechnology company focused on discovering and developing protein therapeutics for diseases. The company's product candidates address patient populations for which therapies are still needed. Its is focused … Full story available on Benzinga.com

Benzinga Feeds | June 22, 2020

Why Five Prime's Stock Is Trading Higher Today

Five Prime Therapeutics (NASDAQ: FPRX) shares are trading higher on Monday after Wedbush upgraded the company's stock from Neutral to Outperform and raised its price target from $5 to $9.Five Prime Therapeutics is a biotechnology company focused on discovering and developing protein therapeutics for diseases. The company's product candidates address patient populations for which therapies are still needed. Its is focused on advancing its internal pipeline and retaining rights for products in targeted specialty markets.It also seeks to establish additional collaborations to supplement its internal development capabilities. These collaborations generate additional funding in order to further validate the company's technology. It has the following product in pipeline: Cabiraliz...

Yahoo | June 22, 2020

Is Five Prime Therapeutics (FPRX) Stock a Solid Choice Right Now?

Five Prime Therapeutics (FPRX) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

Zacks Investment Research | May 15, 2020

Read More 'FPRX' Stories Here

FPRX Price Returns

1-mo 30.49%
3-mo 185.98%
6-mo 22.16%
1-year 0.00%
3-year -80.71%
5-year -75.44%
YTD 33.33%
2019 -50.65%
2018 -57.57%
2017 -56.26%
2016 20.75%
2015 53.70%

Continue Researching FPRX

Here are a few links from around the web to help you further your research on Five Prime Therapeutics Inc's stock as an investment opportunity:

Five Prime Therapeutics Inc (FPRX) Stock Price | Nasdaq
Five Prime Therapeutics Inc (FPRX) Stock Quote, History and News - Yahoo Finance
Five Prime Therapeutics Inc (FPRX) Stock Price and Basic Information | MarketWatch


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 0.8675 seconds.